Antiplatelet Therapy
Introduction to Alternatives
- The European Society of Cardiology and American College of Cardiology/American Heart Association recommend clopidogrel 75 mg daily as a safe and effective alternative to aspirin monotherapy in patients with prior myocardial infarction, remote percutaneous coronary intervention, or atherosclerosis of the extracranial carotid or vertebral arteries, particularly in those with aspirin allergy (Class I, Level A recommendation; Level of Evidence: C) 1, 2, 3
- The American Diabetes Association also recommends clopidogrel (75 mg/day) for patients with cardiovascular disease and documented aspirin allergy (Level B recommendation) 4
Alternative Antiplatelet Agents
- Ticlopidine (250 mg twice daily) may be considered as an alternative to clopidogrel, although it has largely been replaced due to the risk of neutropenia and need for blood monitoring 2, 5
- Cilostazol (100 mg twice daily) may be considered as a substitute for aspirin as part of a dual antiplatelet regimen in patients with aspirin allergy, particularly in those who have undergone stent placement (Grade 2C recommendation) 6
Considerations for Clopidogrel Use
- Clopidogrel effectiveness can be affected by genetic variations in the CYP2C19 enzyme, which may result in reduced conversion to its active metabolite in some patients 2
- No dose adjustment is necessary in patients with renal impairment, but caution is advised in patients with mild-to-moderate hepatic impairment 1
- Clopidogrel works as a P2Y12 receptor antagonist, inhibiting platelet aggregation through ADP receptor blockade rather than prostaglandin pathway inhibition, and does not cross-react with aspirin's mechanism of action 7
- Clopidogrel has a different chemical structure than aspirin and NSAIDs, making cross-reactivity unlikely 7